Your browser is no longer supported. Please, upgrade your browser.
Codiak BioSciences, Inc.
Index- P/E- EPS (ttm)-1.05 Insider Own0.10% Shs Outstand97.52M Perf Week-16.85%
Market Cap292.76M Forward P/E- EPS next Y-3.81 Insider Trans26.50% Shs Float19.20M Perf Month-28.68%
Income-102.50M PEG- EPS next Q-1.09 Inst Own62.50% Short Float3.27% Perf Quarter-56.68%
Sales2.90M P/S100.95 EPS this Y-31.50% Inst Trans- Short Ratio4.40 Perf Half Y6.27%
Book/sh0.15 P/B85.87 EPS next Y9.50% ROA-84.00% Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE60.10% 52W Range7.90 - 37.85 Perf YTD-60.12%
Dividend- P/FCF- EPS past 5Y- ROI-229.60% 52W High-65.97% Beta-
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin- 52W Low63.04% ATR1.50
Employees105 Current Ratio5.30 Sales Q/Q700.00% Oper. Margin- RSI (14)37.57 Volatility9.97% 10.32%
OptionableNo Debt/Eq1.71 EPS Q/Q23.30% Profit Margin- Rel Volume0.53 Prev Close13.31
ShortableYes LT Debt/Eq1.71 Earnings- Payout- Avg Volume142.54K Price12.88
Recom1.50 SMA20-13.32% SMA50-27.29% SMA200-26.07% Volume75,076 Change-3.23%
Nov-09-20Initiated Wedbush Outperform $19
Nov-09-20Initiated Goldman Buy $29
Apr-10-21 08:30AM  
Mar-30-21 09:30AM  
Mar-17-21 07:30AM  
Mar-10-21 04:38PM  
Feb-20-21 01:27AM  
Feb-17-21 04:30PM  
Feb-11-21 10:18PM  
Feb-09-21 04:17PM  
Feb-04-21 07:30AM  
Jan-21-21 09:00AM  
Jan-13-21 11:58PM  
Dec-30-20 07:00AM  
Dec-21-20 09:00AM  
Nov-27-20 11:55AM  
Nov-23-20 07:30AM  
Nov-19-20 04:05PM  
Nov-09-20 08:00AM  
Oct-23-20 06:00PM  
Oct-13-20 07:04PM  
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrison BriggsDirectorFeb 17Buy21.004,76199,9814,761Feb 17 06:05 PM